Summary
263.15
3.35
(1.29%)
07/17/2026
Ascendis Pharma A/S (ASND)Key Facts
Performance
Historical returns1D
1.29%
1W
-3.94%
1M
12.37%
3M
6.94%
6M
26.22%
1Y
48.12%
5Y
114.64%
Snapshot
Key statisticsClose
263.15
Change
3.35
Change %
1.29%
Open
259.61
Day Range
259.50 – 267.50
Volume
453,853
Avg Vol (20d)
881,574
Rel Vol
0.51x
52W Range
160.86 - 281.79
vs 52W High
-6.61%
vs 52W Low
63.59%
Gap
-1.45
Market Cap
USD 12.04B
Beta
0.45
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 2× | -2.02% |
| 1-Month | 7× | -5.06% |
| 3-Month | 9× | -5.06% |
| 6-Month | 14× | -5.06% |
| YTD | 14× | -5.06% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 27× | -5.06% |
| 2-Year | 40× | -5.06% |
| 3-Year | 68× | -5.06% |
| 5-Year | 37× | -5.06% |
| 10-Year | 127× | -5.06% |
Financial SnapshotFY 2025
Full financialsRevenue
USD 691.71M
+90.2% YoY
Net Income
-USD 219.03M
-42.1% YoY
EPS
-3.62
-44.6% YoY
Gross Margin
85.1%
Operating Margin
-18.9%
Net Margin
-31.7%
EBITDA
-USD 113.90M
Free Cash Flow
USD 43.62M
6.3% margin
ROE
134.6%
ROA
-16.8%
Debt / Equity
-5.35x
net debt USD 255.64M
Cash & Equiv.
USD 615.78M
Fundamental Ratings
MainB-
RecommendedNeutral
DCFStrong Sell
ROEStrong Buy
ROAStrong Buy
Debt/EquityStrong Sell
P/ESell
P/BStrong Sell
Latest Earnings
- ASND reported last earnings on 2026-05-07.
- EPS of $0.32 vs $0.1876 estimated — surprise $0.13.
- Revenue of $285M vs $309M estimated — surprise $-24M.
News
All newsWhy Crinetics Stock Soared 99% This Week
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
14 value stocks of companies primed for rapid growth through 2028
Let us begin with a midyear summary of index results that might surprise you in light of the triple-digit gains for so many growth stocks in the S&P 500.
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated...
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part...
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th...
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with...
Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review
The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap Growth Index, for the quarter ended March 31, 2026. Among the top contributors to relative performance during the quarter were Vertiv Holdings, Ascendis Pharma, Howmet Aerospace,...
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, June 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today...
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and...
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage, and reduced financing risk. Yorvipath and Yuviwel...
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma Reports First Quarter 2026 Financial Results
- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare...
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at enrollment treated with once-weekly TransCon CNP (navepegritide) in its pivotal ApproaCH Trial...
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to...
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior Notes due 2028 (the “notes”) (CUSIP No. 04351P AD3 / ISIN No. US04351PAD33) for...
Assetmark Inc. Has $1.83 Million Stake in Ascendis Pharma A/S $ASND
Assetmark Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ: ASND) by 48.1% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,579 shares of the biotechnology company's stock after purchasing an additional 2,787 shares during the...
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq), replacing the listing of American Depositary Shares (ADSs). The ordinary shares trade under the...
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held - Simplified listing structure intended to enable enhanced depth and breadth of...
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia
- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community